This title appears in the Scientific Report :
2015
Please use the identifier:
http://dx.doi.org/10.1093/neuonc/nov088 in citations.
The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma
The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma
Background We evaluated the diagnostic value of static and dynamic O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) PET parameters in patients with progressive or recurrent glioma.Methods We retrospectively analyzed 132 dynamic 18F-FET PET and conventional MRI scans of 124 glioma patients (primary World...
Saved in:
Personal Name(s): | Galldiks, N. (Corresponding author) |
---|---|
Stoffels, G. / Filss, C. / Rapp, M. / Blau, T. / Tscherpel, C. / Ceccon, G. / Dunkl, V. / Weinzierl, M. / Stoffel, M. / Sabel, M. / Fink, G. R. / Shah, N. J. / Langen, K.-J. | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 JARA-BRAIN; JARA-BRAIN Physik der Medizinischen Bildgebung; INM-4 |
Published in: | Neuro-Oncology, 17 (2015) 9, S. 1293-1300 |
Imprint: |
Oxford
Oxford Univ. Press
2015
|
DOI: |
10.1093/neuonc/nov088 |
PubMed ID: |
26008606 |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging |
Publikationsportal JuSER |
Background We evaluated the diagnostic value of static and dynamic O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) PET parameters in patients with progressive or recurrent glioma.Methods We retrospectively analyzed 132 dynamic 18F-FET PET and conventional MRI scans of 124 glioma patients (primary World Health Organization grade II, n = 55; grade III, n = 19; grade IV, n = 50; mean age, 52 ± 14 y). Patients had been referred for PET assessment with clinical signs and/or MRI findings suggestive of tumor progression or recurrence based on Response Assessment in Neuro-Oncology criteria. Maximum and mean tumor/brain ratios of 18F-FET uptake were determined (20–40 min post-injection) as well as tracer uptake kinetics (ie, time to peak and patterns of the time–activity curves). Diagnoses were confirmed histologically (95%) or by clinical follow-up (5%). Diagnostic accuracies of PET and MR parameters for the detection of tumor progression or recurrence were evaluated by receiver operating characteristic analyses/chi-square test.Results Tumor progression or recurrence could be diagnosed in 121 of 132 cases (92%). MRI and 18F-FET PET findings were concordant in 84% and discordant in 16%. Compared with the diagnostic accuracy of conventional MRI to diagnose tumor progression or recurrence (85%), a higher accuracy (93%) was achieved by 18F-FET PET when a mean tumor/brain ratio ≥2.0 or time to peak <45 min was present (sensitivity, 93%; specificity, 100%; accuracy, 93%; positive predictive value, 100%; P < .001).Conclusion Static and dynamic 18F-FET PET parameters differentiate progressive or recurrent glioma from treatment-related nonneoplastic changes with higher accuracy than conventional MRI. |